Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Brian Druker, François Guilhot, Stephen G. O’Brien et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text

Medicine, Hematology, Oncology +13

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

Joerg Hasford, Michele Baccarani, Verena Hoffmann et al. · Blood · 2011 · 497 citations · Full text

Life Sciences, Biostatistics, Oncology +13

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C.P. Cross et al. · Blood · 2008 · 389 citations · Full text

Medicine, Biostatistics, Performance Measurement +9

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

Magnus Björkholm, Lotta Ohm, Sandra Eloranta et al. · Journal of Clinical Oncology · 2011 · 214 citations

Medicine, Oncology, Pharmacology +13